Gryphon Bio is a preclinical-stage therapeutic bioconjugate company created to harness our co-founders' discovery of unexpected waves of molecules as novel therapeutic targets and temporal biomarkers in the blood to accelerate central nervous system (CNS) repair.
We are developing a promising, diversified pipeline of lead therapeutic bioconjugates to accelerate CNS repair by following clues from nature’s sequence of cellular and molecular events. Each compound has a unique mechanism(s) of action (MOA) and pharmacokinetic/pharmacodynamic (PK/PD) profile, compelling biology, and binds to a novel or de-risked therapeutic target(s).
Mission: To develop and market the first therapeutic bioconjugate to accelerate CNS repair.
Vision: To pioneer therapeutic bioconjugates as safe and efficacious CNS medicines to improve the lives of patients.
OUR COURAGEOUS PATIENTS
CNS diseases are leading causes of death and disability, including:
Traumatic brain injury (TBI)
Multiple sclerosis (MS)
Post-traumatic epilepsy (PTE)
Alzheimer's disease (AD)
Alzheimer's disease-related dementias (ADRD)
Chronic traumatic encephalopathy (CTE)
Frontotemporal degeneration (FTD)
Spinal cord injury (SCI)
OUR COURAGEOUS TEAM
We are a proven, cohesive, interdisciplinary and internationally recognized team with deep experience in drug development (e.g., therapeutic bioconjugates), business development (e.g., licensing, intellectual property and partnerships) and CNS biomarker development (e.g., TBI). Together with our advisors, we have 1000+ previous peer-reviewed publications and $100M+ in previous grant awards. Moreover, we have successfully led several preclinical and clinical studies on successful high impact assets in industry and academe.
If you want to learn more about our amazing team members, get in touch.
MEDIA & PRESS UPDATES